文献速递白血病淋巴瘤

伊诺妥珠单抗:从临床前开发到治疗B细胞急性淋巴细胞白血病的成功

Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2019-01-01

伊诺妥珠单抗奥唑米星(InO)是靶向CD22的抗体药物偶联物,已获美国FDA批准用于复发/难治性B细胞急性淋巴细胞白血病(ALL)。随机3期试验显示,InO组完全缓解率80.7% vs 化疗组29.4%(P < .001),微小残留病阴性率78.4% vs 28.1%(P < .001)。

要点

  • InO为CD22靶向抗体药物偶联物,获批用于复发/难治性B细胞ALL。
  • 3期试验中InO完全缓解率80.7% vs 化疗29.4%(P < .001)。
  • InO组微小残留病阴性率78.4% vs 化疗28.1%(P < .001)。

核心结论

  • InO在复发/难治性B细胞ALL中优于标准治疗方案,完全缓解率和微小残留病阴性率均显著提高。
  • InO特异性副作用包括肝静脉闭塞病,已有共识指南用于减少毒性。
  • 正在进行的试验探索InO联合其他药物用于复发场景及加入一线治疗。

研究设计与样本

  • 综述,详述InO的临床前和临床开发,聚焦最佳使用方法和未来发展方向。
  • 关键证据来自随机3期试验:比较InO与研究者选择化疗在复发或难治性急性淋巴细胞白血病患者中的疗效。

主要发现

  • InO组完全缓解率为80.7%,化疗组为29.4%(P < .001)。
  • InO组达到完全缓解且微小残留病不可检测的患者比例为78.4%,化疗组为28.1%(P < .001)。
  • InO最初因临床前模型活性和惰性淋巴瘤高缓解率而开发用于非霍奇金淋巴瘤,但3期试验阴性,后续开发转向CD22+ ALL。

关键数值与推荐

  • InO由靶向CD22的免疫球蛋白G4人源化单克隆抗体与卡奇霉素偶联而成。
  • 美国食品药品监督管理局(FDA)已批准InO用于治疗复发/难治性B细胞急性淋巴细胞白血病(ALL)。
  • 针对InO特异性副作用(包括肝静脉闭塞病)的共识指南已可用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inotuzumab ozogamicin (InO) is a recently US Food and Drug Administration-approved antibody-drug conjugate for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). InO consists of a CD22-targeting immunoglobulin G4 humanized monoclonal antibody conjugated to calicheamicin. Although initially developed for the treatment of non-Hodgkin lymphoma (NHL) because of activity in preclinical models and high response rates in indolent lymphomas, a phase 3 trial was negative and further development focused on CD22+ ALL. Although results in NHL were disappointing, parallel testing in early-phase trials of CD22+ ALL demonstrated feasibility and efficacy. Subsequently, the randomized phase 3 Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia trial showed that InO was superior to standard of care regimens with a significantly improved complete remission (CR) rate in patients with relapsed/refractory disease (80.7% vs 29.4%, P < .001). Patients achieving CR with InO also had a significantly higher rate of undetectable minimal residual disease compared with chemotherapy (78.4% vs 28.1%, P < .001). InO-specific side effects, including veno-occlusive disease, have been an ongoing area of concern, and consensus guidelines for minimizing toxicities are now available. Ongoing trials are investigating the combination of InO with other agents in the relapse setting and the addition of InO to frontline therapy. This review details the preclinical and clinical development of InO, focusing on how best to use it and future directions for further development.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wynne J, Wright D, Stock W, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019. PMID: 30622147. doi:10.1182/bloodadvances.2018026211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。